Q-omics provides the consensus-scored MX1 profile across patient tissues and cancer cell-line models. MX1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MX1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MX1 RNA expression shows 14,692 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where MX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MX1 survival associations across molecular data types. MX1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MX1 RNA expression–survival associations across cancer types. High MX1 expression shows unfavorable associations in KIRC, LGG, UCEC, LAML and HNSC, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MX1 RNA expression.
This table summarizes MX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MX1 shows lower tumor expression in KICH and higher tumor expression in HNSC, BRCA, BLCA, STAD and KIRC. The HNSC box plot shows higher MX1 RNA expression in tumor versus normal tissue (log2 FC = +1.182, t-test p < 0.001).
This table shows molecular features associated with MX1 in patient tissues and cancer cell lines. In patient samples, MX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
